{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:12:54Z","timestamp":1793722374295,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2015.12.071","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:35:12Z","timestamp":1457656512000},"page":"2992-2995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["Status of vaccine research and development of vaccines for leishmaniasis"],"prefix":"10.1016","volume":"34","author":[{"given":"Portia M.","family":"Gillespie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coreen M.","family":"Beaumier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.12.071_bib0190","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1377\/hlthaff.2011.0317","article-title":"A handful of \u2018antipoverty\u2019 vaccines exist for neglected diseases, but the world's poorest billion people need more","volume":"30","author":"Hotez","year":"2011","journal-title":"Health Aff"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.2012.11-0814","article-title":"The four horsemen of the apocalypse: tropical medicine in the fight against plague, death, famine, and war","volume":"87","author":"Hotez","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0200","series-title":"Leishmaniasis","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0205","doi-asserted-by":"crossref","first-page":"e2865","DOI":"10.1371\/journal.pntd.0002865","article-title":"The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases","volume":"8","author":"Hotez","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0210","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","author":"Global Burden of Disease Study C","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0215","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.1990.43.619","article-title":"Leishmania mexicana complex: human infections in the Republic of Panama","volume":"43","author":"de Vasquez","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0220","series-title":"Chagas disease (American trypanosomiasis)","author":"WHO","year":"2015"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2015.12.071_bib0225","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0035-9203(01)90218-4","article-title":"Leishmaniasis in Sudan. Visceral leishmaniasis","volume":"95","author":"Zijlstra","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0230","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ije\/25.4.862","article-title":"The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994","volume":"25","author":"Seaman","year":"1996","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0235","series-title":"2014 Ebola outbreak in West Africa \u2013 case counts","author":"CDC","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0240","series-title":"Leishmaniasis: the neglected disease of war, conflict, and human misery","author":"Hotez","year":"2014"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.trsl.2013.03.006","article-title":"New vaccines for neglected parasitic diseases and dengue","volume":"162","author":"Beaumier","year":"2013","journal-title":"Transl Res: J Lab Clin Med"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0250","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.1507782112","article-title":"DDT-based indoor residual spraying suboptimal for visceral leishmaniasis elimination in India","volume":"112","author":"Coleman","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0255","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4269\/ajtmh.2012.10-0492","article-title":"Leishmania infantum chagasi in northeastern Brazil: asymptomatic infection at the urban perimeter","volume":"86","author":"Lima","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0265","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vaccine.2012.11.032","article-title":"The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas","volume":"31","author":"Bacon","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4269\/ajtmh.2012.10-0415","article-title":"The economic value of a visceral leishmaniasis vaccine in Bihar state, India","volume":"86","author":"Lee","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0275","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.intimp.2011.05.008","article-title":"Vaccine candidates for leishmaniasis: a review","volume":"11","author":"Nagill","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.12.071_bib0280","doi-asserted-by":"crossref","first-page":"B244","DOI":"10.1016\/j.vaccine.2012.11.080","article-title":"Case study for a vaccine against leishmaniasis","volume":"31","author":"Alvar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0285","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(98)09552-X","article-title":"Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran","volume":"351","author":"Sharifi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0290","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fimmu.2012.00144","article-title":"Adjuvants for Leishmania vaccines: from models to clinical application","volume":"3","author":"Raman","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0295","first-page":"1","article-title":"An overview on Leishmania vaccines: a narrative review article","volume":"6","author":"Rezvan","year":"2015","journal-title":"Vet Res Forum"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0300","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0305","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0315","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.meegid.2014.07.028","article-title":"What's behind a sand fly bite? The profound effect of sand fly saliva on host hemostasis, inflammation and immunity","volume":"28","author":"Abdeladhim","year":"2014","journal-title":"Infect Genet Evol: J Mol Epidemiol Evol Genet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0320","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fpubh.2014.00099","article-title":"Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?","volume":"2","author":"Kamhawi","year":"2014","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3043","article-title":"A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates","volume":"7","author":"Oliveira","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0330","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0335","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1016\/j.vaccine.2010.07.063","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis","volume":"28","author":"Nascimento","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0340","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis","volume":"28","author":"Llanos-Cuentas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0345","series-title":"A study of the efficacy and safety of the LEISH-F2+MPL-SE vaccine for treatment of cutaneous leishmaniasis","author":"ClinicalTrials.gov","year":"2013"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0350","series-title":"LEISH-F3+GLA-SE and the LEISH-F3+MPL-SE vaccine","author":"ClinicalTrials.gov","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0355","series-title":"Multivalent vaccine for human visceral leishmaniasis","author":"MuLeVaClin","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0360","series-title":"G-Finder","author":"Policy_Cures","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0365","series-title":"Phase 1 LEISH-F3+SLA-SE vaccine trial in healthy adult volunteers","author":"ClinicalTrials.gov","year":"2015"},{"key":"10.1016\/j.vaccine.2015.12.071_bib0370","series-title":"Immune responses after human subject challenge with sand fly bites","author":"ClinicalTrials.gov","year":"2015"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T07:53:00Z","timestamp":1536911580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16002899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":37,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16002899"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of vaccine research and development of vaccines for leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}